Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Down 99.9% in April

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the target of a significant decline in short interest in April. As of April 15th, there was short interest totaling 16 shares, a decline of 99.9% from the March 31st total of 15,516 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily volume of 356,323 shares, the days-to-cover ratio is presently 0.0 days.

Oncotelic Therapeutics Stock Performance

Oncotelic Therapeutics stock opened at $0.04 on Friday. Oncotelic Therapeutics has a 12-month low of $0.02 and a 12-month high of $0.11. The company has a quick ratio of 0.07, a current ratio of 0.07 and a debt-to-equity ratio of 0.01. The business’s 50-day moving average price is $0.04 and its two-hundred day moving average price is $0.07. The stock has a market cap of $16.75 million, a PE ratio of 0.06 and a beta of -0.59.

Oncotelic Therapeutics (OTCMKTS:OTLC) last announced its quarterly earnings results on Wednesday, April 15th. The company reported $0.59 EPS for the quarter.

About Oncotelic Therapeutics

Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.